Abstract
Aims/hypothesis Micro- and macrovascular complications are common among persons with type 2 diabetes. Interest into the potential of circulating small non-coding RNAs (sRNAs) as biomarkers or drivers of the development of diabetic complications is growing. In this study we investigated if circulating sRNAs levels associate with prevalent chronic kidney disease (CKD) in persons with type 2 diabetes.
Methods Plasma sRNAs levels were determined using sRNA-seq, allowing detection of miRNAs, snoRNAs, piRNAs, tRNA-fragments and various other sRNA classes, in persons with type 2 diabetes, with CKD (n=69) or without CKD (n=405). Multiple regression analyses were used to test for associations between the sRNAs and primary endpoint CKD. In secondary analyses, we also tested the association with eGFR and albuminuria (UACR).
Results In total, twelve sRNA were associated with prevalent CKD (logFC = -0.32 to -1.28, all P≤6.24×10−4). Although miRNAs represent the majority of the sRNAs measured (64%) only four miRNA were significantly associated with prevalent CKD. Interestingly, the majority of the significant sRNA belonged to the snoRNAs (58%). Similar results were observed for eGFR and UACR. Only one of the twelve sRNAs showed its highest expression in kidney whereas several others showed high expression in liver or colon.
Conclusions/interpretation Small RNAs present in the circulation associate with CKD in persons with type 2 diabetes. Further studies are warranted to elucidate the biological role of sRNA in diabetic CKD and in particular snoRNAs. High expression of these circulating sRNAs in tissues other than kidney suggest a role in inter-organ communication.
Research in context
What is already known about this subject? (maximum of 3 bullet points)
miRNAs present in the circulation have been associated with CKD in diabetes.
The role of other small non-coding RNAs, for example snoRNAs, have not been studied.
What is the key question? (one bullet point only; formatted as a question)
Are circulating small RNAs, such as miRNA, snoRNAs, tRNA fragments and piRNAs associated with CKD in persons with type 2 diabetes (n=475)?
What are the new findings? (maximum of 3 bullet points)
Twelve small RNAs associate with prevalent CKD in type 2 diabetes.
Especially snoRNAs are more frequently associated with CKD.
Identified circulating small RNAs are often expressed in tissues other than kidney, which suggest a role for these small non-coding RNAs in inter-organ communication.
How might this impact on clinical practice in the foreseeable future? (one bullet point only)
Circulating small RNAs and especially snoRNAs might represent novel mechanisms and therapeutic targets for CKD in diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a diabetes breakthrough grant from the Dutch Diabetes Research Foundation and ZonMw (grant number 459001015) and a grant from the EFSD/Boehringer Ingelheim European Research Programme on Multi-System Challenges in Diabetes 2021. The study sponsors/funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the ethics committee of the Amsterdam University Medical Center, location VUmc. All participants provided informed consent prior to this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
